Table 1 Clinical outcomes of tissue-specific glucocorticoid excess [139–142]
Tissue/system | Symptom |
|---|---|
Nervous system | Anxiety |
| Â | Insomnia |
| Â | Depression |
| Â | Memory dysfunction |
Liver | Gluconeogenesis |
| Â | Lipogenesis |
Skeletal muscle | Insulin resistance |
| Â | Atrophy |
| Â | Fatigue |
Bone | Osteoporosis |
Blood | Elevated blood glucose |
| Â | Impaired fasting glucose |
| Â | Hypokalaemia |
| Â | Dyslipidaemia |
Adipose tissue | Obesity |
| Â | Fat redistribution |
| Â | Weight gain |
Cardiovascular system | Hypertension |
| Â | Pre-eclampsia |
| Â | Sodium/water retention |
| Â | Oedema |
Immune system | Immune suppression - infections |
| Â | Delayed wound healing |
Skin | Hirsuitism |
| Â | Striae |
| Â | Bruising |
| Â | Thinning |
| Â | Acne |
| Â | Delayed wound healing |
Other | Dyspepsia |
Increased appetite | |
Impaired growth in children | |
Suppressed HPA-axis function | |
Cataracts | |
Glaucoma |